Modalities to decrease stromal herpes simplex keratitis reactivation rates

Archives of Ophthalmology

Volumn 127, Issue 7, 2009, Pages 852-856

  Sheppard, John D ^a,b   Wertheimer, Michael L ^a   Scoper, Stephen V ^b  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b Virginia Eye Consultants   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CYCLOSPORIN A; LOTEPREDNOL ETABONATE; PREDNISOLONE ACETATE; VALACICLOVIR;

ADULT; ARTICLE; CAUTERIZATION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; DRY EYE; EMULSION; FEMALE; HERPES SIMPLEX KERATITIS; HUMAN; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VIRUS REACTIVATION;

ACYCLOVIR; ADMINISTRATION, TOPICAL; ANTIVIRAL AGENTS; COMBINED MODALITY THERAPY; CORNEAL STROMA; CYCLOSPORINE; DRUG THERAPY, COMBINATION; DRY EYE SYNDROMES; ELECTROCOAGULATION; EYELIDS; GLUCOCORTICOIDS; HERPESVIRUS 1, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KERATITIS, HERPETIC; LACRIMAL APPARATUS; RECURRENCE; RETROSPECTIVE STUDIES; VALINE; VIRUS ACTIVATION;

EID: 67650466177     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2009.163     Document Type: Article

References (15)

1. Judge A, Assil K. Herpes simplex. http://www.emedicine.com/oph/topic256. htm. Accessed September 24, 2005.
2. Liesegang TJ. Herpes simplex virus epidemiology and ocular importance. Cornea. 2001;20(1):1-13.
3. Doymaz MZ, Rouse BT. Herpetic stromal keratitis: an immunopathologic disease mediated by CD4+ T lymphocytes. Invest Ophthalmol Vis Sci. 1992;33 (7):2165-2173.
4. Keijser S, van Best JA, Van der Lelij A, Jager MJ. Reflex and steady state tears in patients with latent stromal herpetic keratitis. Invest Ophthalmol Vis Sci. 2002; 43(1):87-91.
5. Herpetic Eye Disease Study Group. A controlled trial of oral acyclovir for the prevention of stromal keratitis or iritis in patients with herpes simplex virus epithelial keratitis: the Epithelial Keratitis Trial [published correction appears in Arch Ophthalmol. 1997;115(9):1196]. Arch Ophthalmol. 1997;115(6):703-712.
6. Herpetic Eye Disease Study Group. Acyclovir for the prevention of recurrent herpes simplex virus eye disease. N Engl J Med. 1998;339(5):300-306.
7. Barron BA, Gee L, Hauck WW, et al. Herpetic Eye Disease Study: a controlled trial of oral acyclovir for herpes simplex stromal keratitis. Ophthalmology. 1994; 101(12):1871-1882.
8. Wilhelmus KR, Gee L, Hauck WW, et al. Herpetic Eye Disease Study: a controlled trial of topical corticosteroids for herpes simplex stromal keratitis. Ophthalmology. 1994;101(12):1883-1896.
9. Heiligenhaus A, Steuhl KP. Treatment of HSV-1 stromal keratitis with topical cyclosporin A: a pilot study. Graefes Arch Clin Exp Ophthalmol. 1999;237(5): 435-438.
10. Rao SN. Treatment of herpes simplex virus stromal keratitis unresponsive to topical prednisolone 1% with topical cyclosporine 0.05%. Am J Ophthalmol. 2006; 141(4):771-772.
11. Sall K, Stevenson OD, Mundorf TK, Reis BL; CsA Phase 3 Study Group. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease [published correction appears in Ophthalmology. 2000;107(7):1220]. Ophthalmology. 2000;107: 631-639.
12. Barber LD, Pflugfelder SC, Tauber J, Foulks GN. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology. 2005;112(10):1790-1794.
13. Small DS, Acheampong A, Reis B, et al. Blood concentrations of cyclosporine a during long-term treatment with cyclosporine A ophthalmic emulsions in patients with moderate to severe dry eye disease. J Ocul Pharmacol Ther. 2002; 18(5):411-418.
14. Drugstore.com online pharmacy. http://www.drugstore.com. Accessed April 22, 2009.
15. Hutnik CM, Probst LE. Argon laser punctal therapy vs thermal cautery for the treatment of aqueous deficiency dry eye syndrome. Can J Ophthalmol. 1998; 33(7):365-372.